Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.Leucovorin: The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS.Organoplatinum Compounds: Organic compounds which contain platinum as an integral part of the molecule.Camptothecin: An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Antibodies, Monoclonal, Humanized: Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.Drug Administration Schedule: Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.Sarcoma, Kaposi: A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.Herpesvirus 8, Human: A species in the genus RHADINOVIRUS, subfamily GAMMAHERPESVIRINAE, isolated from patients with AIDS-related and "classical" Kaposi sarcoma.Viral Load: The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression.Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.HIV-1: The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.Herpesvirus 6, Human: The type species of ROSEOLOVIRUS isolated from patients with AIDS and other LYMPHOPROLIFERATIVE DISORDERS. It infects and replicates in fresh and established lines of hematopoietic cells and cells of neural origin. It also appears to alter NK cell activity. HHV-6; (HBLV) antibodies are elevated in patients with AIDS, Sjogren's syndrome, sarcoidosis, chronic fatigue syndrome, and certain malignancies. HHV-6 is the cause of EXANTHEMA SUBITUM and has been implicated in encephalitis.HIV Infections: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).T-Lymphocytes: Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.Apiaceae: A large plant family in the order Apiales, also known as Umbelliferae. Most are aromatic herbs with alternate, feather-divided leaves that are sheathed at the base. The flowers often form a conspicuous flat-topped umbel. Each small individual flower is usually bisexual, with five sepals, five petals, and an enlarged disk at the base of the style. The fruits are ridged and are composed of two parts that split open at maturity.Acorus: A plant genus of the family ACORACEAE, order Arales, subclass Arecidae most notable for Acorus calamus L. root which contains asarone and has been used in TRADITIONAL MEDICINE.Pimenta: A plant genus in the family MYRTACEAE, order Myrtales, subclass Rosidae. It is best known for allspice from the dried berry of Pimenta diocia.Piper nigrum: A plant species in the PIPERACEAE plant family. It is a common spice on foods and is used medicinally to increase gastrointestinal assimilation of other supplements and drugs. Piperine is a key component. Black pepper is picked unripe and heaped for a few days to ferment. White Pepper is the ripe fruit dehulled by maceration in water.Myrtaceae: The myrtle plant family of the order Myrtales. It includes several aromatic medicinal plants such as EUCALYPTUS.Acoraceae: A plant family of the order Arales, subclass Arecidae, class Liliopsida (monocot).Black Pepper: A common spice from fruit of PIPER NIGRUM. Black pepper is picked unripe and heaped for a few days to ferment. White Pepper is the ripe fruit dehulled by maceration in water. Piperine is a key component used medicinally to increase gastrointestinal assimilation of other supplements and drugs.Spices: The dried seeds, bark, root, stems, buds, leaves, or fruit of aromatic plants used to season food.Cuscuta: A plant genus of the family Cuscutaceae. It is a threadlike climbing parasitic plant that is used in DRUGS, CHINESE HERBAL.Asteraceae: A large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of "daisy" refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.Noscapine: A naturally occurring opium alkaloid that is a centrally acting antitussive agent.Tubulin Modulators: Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES.DioxolesMicrotubules: Slender, cylindrical filaments found in the cytoskeleton of plant and animal cells. They are composed of the protein TUBULIN and are influenced by TUBULIN MODULATORS.Cell Polarity: Orientation of intracellular structures especially with respect to the apical and basolateral domains of the plasma membrane. Polarized cells must direct proteins from the Golgi apparatus to the appropriate domain since tight junctions prevent proteins from diffusing between the two domains.Colchicine: A major alkaloid from Colchicum autumnale L. and found also in other Colchicum species. Its primary therapeutic use is in the treatment of gout, but it has been used also in the therapy of familial Mediterranean fever (PERIODIC DISEASE).Demecolcine: An alkaloid isolated from Colchicum autumnale L. and used as an antineoplastic.Von Hippel-Lindau Tumor Suppressor Protein: A ubiquitin-protein ligase that mediates OXYGEN-dependent polyubiquitination of HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT. It is inactivated in VON HIPPEL-LINDAU SYNDROME.Cell Movement: The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.Neovascularization, Physiologic: The development of new BLOOD VESSELS during the restoration of BLOOD CIRCULATION during the healing process.Peer Group: Group composed of associates of same species, approximately the same age, and usually of similar rank or social status.Video Games: A form of interactive entertainment in which the player controls electronically generated images that appear on a video display screen. This includes video games played in the home on special machines or home computers, and those played in arcades.Videotape Recording: Recording of visual and sometimes sound signals on magnetic tape.Periodicals as Topic: A publication issued at stated, more or less regular, intervals.Journal Impact Factor: A quantitative measure of the frequency on average with which articles in a journal have been cited in a given period of time.Peer Review, Research: The evaluation by experts of the quality and pertinence of research or research proposals of other experts in the same field. Peer review is used by editors in deciding which submissions warrant publication, by granting agencies to determine which proposals should be funded, and by academic institutions in tenure decisions.Peer Review: An organized procedure carried out by a select committee of professionals in evaluating the performance of other professionals in meeting the standards of their specialty. Review by peers is used by editors in the evaluation of articles and other papers submitted for publication. Peer review is used also in the evaluation of grant applications. It is applied also in evaluating the quality of health care provided to patients.Television: The transmission and reproduction of transient images of fixed or moving objects. An electronic system of transmitting such images together with sound over a wire or through space by apparatus that converts light and sound into electrical waves and reconverts them into visible light rays and audible sound. (From Webster, 3rd ed)Publishing: "The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.Bibliometrics: The use of statistical methods in the analysis of a body of literature to reveal the historical development of subject fields and patterns of authorship, publication, and use. Formerly called statistical bibliography. (from The ALA Glossary of Library and Information Science, 1983)Patents as Topic: Exclusive legal rights or privileges applied to inventions, plants, etc.Tumor Necrosis Factor Ligand Superfamily Member 13: A member of tumor necrosis factor superfamily found on MACROPHAGES; DENDRITIC CELLS and T-LYMPHOCYTES. It occurs as transmembrane protein that can be cleaved to release a secreted form that specifically binds to TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; and B CELL MATURATION ANTIGEN.Inventions: A novel composition, device, or process, independently conceived de novo or derived from a pre-existing model.Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.B-Lymphocytes: Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.Immunoglobulin A: Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions.Immunoglobulin G: The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.B-Lymphocyte Subsets: A classification of B-lymphocytes based on structurally or functionally different populations of cells.Antibody-Producing Cells: Cells of the lymphoid series that can react with antigen to produce specific cell products called antibodies. Various cell subpopulations, often B-lymphocytes, can be defined, based on the different classes of immunoglobulins that they synthesize.Immunoglobulin M: A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Karnofsky Performance Status: A performance measure for rating the ability of a person to perform usual activities, evaluating a patient's progress after a therapeutic procedure, and determining a patient's suitability for therapy. It is used most commonly in the prognosis of cancer therapy, usually after chemotherapy and customarily administered before and after therapy. It was named for Dr. David A. Karnofsky, an American specialist in cancer chemotherapy.Dacarbazine: An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)Antineoplastic Agents, Alkylating: A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)Drug Delivery Systems: Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.Microtechnology: Manufacturing technology for making microscopic devices in the micrometer range (typically 1-100 micrometers), such as integrated circuits or MEMS. The process usually involves replication and parallel fabrication of hundreds or millions of identical structures using various thin film deposition techniques and carried out in environmentally-controlled clean rooms.Drug Carriers: Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers.Capsules: Hard or soft soluble containers used for the oral administration of medicine.Delayed-Action Preparations: Dosage forms of a drug that act over a period of time by controlled-release processes or technology.Nanocapsules: Nanometer-sized, hollow, spherically-shaped objects that can be utilized to encapsulate small amounts of pharmaceuticals, enzymes, or other catalysts (Glossary of Biotechnology and Nanobiotechnology, 4th ed).Illusions: The misinterpretation of a real external, sensory experience.Nebulizers and Vaporizers: Devices that cause a liquid or solid to be converted into an aerosol (spray) or a vapor. It is used in drug administration by inhalation, humidification of ambient air, and in certain analytical instruments.Metered Dose Inhalers: A small aerosol canister used to release a calibrated amount of medication for inhalation.

COMP-Ang1: a designed angiopoietin-1 variant with nonleaky angiogenic activity. (1/26)

Angiopoietin-1 (Ang1) has potential therapeutic applications in inducing angiogenesis, enhancing endothelial cell survival, and preventing vascular leakage. However, production of Ang1 is hindered by aggregation and insolubility resulting from disulfide-linked higher-order structures. Here, by replacing the N-terminal portion of Ang1 with the short coiled-coil domain of cartilage oligomeric matrix protein (COMP), we have generated a soluble, stable, and potent Ang1 variant, COMP-Ang1. This variant is more potent than native Ang1 in phosphorylating the tyrosine kinase with Ig and epidermal growth factor homology domain 2 (Tie2) receptor and Akt in primary cultured endothelial cells, enhancing angiogenesis in vitro and increasing adult angiogenesis in vivo. Thus, COMP-Ang1 is an effective alternative to native Ang1 for therapeutic angiogenesis in vivo.  (+info)

Current methods for assaying angiogenesis in vitro and in vivo. (2/26)

Angiogenesis, the development of new blood vessels from an existing vasculature, is essential in normal developmental processes and in numerous pathologies, including diabetic retinopathy, psoriasis and tumour growth and metastases. One of the problems faced by angiogenesis researchers has been the difficulty of finding suitable methods for assessing the effects of regulators of the angiogenic response. The ideal assay would be reliable, technically straightforward, easily quantifiable and, most importantly, physiologically relevant. Here, we review the advantages and limitations of the principal assays in use, including those for the proliferation, migration and differentiation of endothelial cells in vitro, vessel outgrowth from organ cultures and in vivo assays such as sponge implantation, corneal, chamber, zebrafish, chick chorioallantoic membrane (CAM) and tumour angiogenesis models.  (+info)

Acclimatization to 4100 m does not change capillary density or mRNA expression of potential angiogenesis regulatory factors in human skeletal muscle. (3/26)

Increased skeletal muscle capillary density would be a logical adaptive mechanism to chronic hypoxic exposure. However, animal studies have yielded conflicting results, and human studies are sparse. Neoformation of capillaries is dependent on endothelial growth factors such as vascular endothelial growth factor (VEGF), a known target gene for hypoxia inducible factor 1 (HIF-1). We hypothesised that prolonged exposure to high altitude increases muscle capillary density and that this can be explained by an enhanced HIF-1alpha expression inducing an increase in VEGF expression. We measured mRNA levels and capillary density in muscle biopsies from vastus lateralis obtained in sea level residents (SLR; N=8) before and after 2 and 8 weeks of exposure to 4100 m altitude and in Bolivian Aymara high-altitude natives exposed to approximately 4100 m altitude (HAN; N=7). The expression of HIF-1alpha or VEGF mRNA was not changed with prolonged hypoxic exposure in SLR, and both genes were similarly expressed in SLR and HAN. In SLR, whole body mass, mean muscle fibre area and capillary to muscle fibre ratio remained unchanged during acclimatization. The capillary to fibre ratio was lower in HAN than in SLR (2.4+/-0.1 vs 3.6+/-0.2; P<0.05). In conclusion, human muscle VEGF mRNA expression and capillary density are not significantly increased by 8 weeks of exposure to high altitude and are not increased in Aymara high-altitude natives compared with sea level residents.  (+info)

Bartonella adhesin a mediates a proangiogenic host cell response. (4/26)

Bartonella henselae causes vasculoproliferative disorders in humans. We identified a nonfimbrial adhesin of B. henselae designated as Bartonella adhesin A (BadA). BadA is a 340-kD outer membrane protein encoded by the 9.3-kb badA gene. It has a modular structure and contains domains homologous to the Yersinia enterocolitica nonfimbrial adhesin (Yersinia adhesin A). Expression of BadA was restored in a BadA-deficient transposon mutant by complementation in trans. BadA mediates the binding of B. henselae to extracellular matrix proteins and to endothelial cells, possibly via beta1 integrins, but prevents phagocytosis. Expression of BadA is crucial for activation of hypoxia-inducible factor 1 in host cells by B. henselae and secretion of proangiogenic cytokines (e.g., vascular endothelial growth factor). BadA is immunodominant in B. henselae-infected patients and rodents, indicating that it is expressed during Bartonella infections. Our results suggest that BadA, the largest characterized bacterial protein thus far, is a major pathogenicity factor of B. henselae with a potential role in the induction of vasculoproliferative disorders.  (+info)

Vascular endothelial growth factor and angiogenesis. (5/26)

Angiogenesis is a hallmark of wound healing, the menstrual cycle, cancer, and various ischemic and inflammatory diseases. A rich variety of pro- and antiangiogenic molecules have already been discovered. Vascular endothelial growth factor (VEGF) is an interesting inducer of angiogenesis and lymphangiogenesis, because it is a highly specific mitogen for endothelial cells. Signal transduction involves binding to tyrosine kinase receptors and results in endothelial cell proliferation, migration, and new vessel formation. In this article, the role of VEGF in physiological and pathological processes is reviewed. We also discuss how modulation of VEGF expression creates new therapeutic possibilities and describe recent developments in this field.  (+info)

The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. (6/26)

The receptor tyrosine kinase EphB4 and its ligand EphrinB2 play a crucial role in vascular development during embryogenesis. The soluble monomeric derivative of the extracellular domain of EphB4 (sEphB4) was designed as an antagonist of EphB4/EphrinB2 signaling. sEphB4 blocks activation of EphB4 and EphrinB2; suppresses endothelial cell migration, adhesion, and tube formation in vitro; and inhibits the angiogenic effects of various growth factors (VEGF and bFGF) in vivo. sEphB4 also inhibits tumor growth in murine tumor xenograft models. sEphB4 is thus a therapeutic candidate for vascular proliferative diseases and cancer.  (+info)

New insights into the biology of preeclampsia. (7/26)

Despite recent research progress, the biology of preeclampsia is still poorly understood and neither effective prediction nor causal therapy have yet emerged. Nevertheless, recent studies have documented new and exciting pathophysiological mechanisms for the origin and development of preeclampsia. These studies provide a more differentiated view on alterations of particular peptide systems with strong impact on angiogenesis and cardiovascular regulation in this pregnancy disorder. With the identification of the antiangiogenic factor soluble fms-like tyrosine kinase 1 and the agonistic autoantibody to the angiotensin II type 1 receptor, two factors have been described with a clear linkage to the development of the disease. This review focuses on the most recent and relevant insights into the biology of preeclampsia and develops hypotheses regarding possible links between the reported aspects of preeclampsia.  (+info)

A cell-based model exhibiting branching and anastomosis during tumor-induced angiogenesis. (8/26)

This work describes the first cell-based model of tumor-induced angiogenesis. At the extracellular level, the model describes diffusion, uptake, and decay of tumor-secreted pro-angiogenic factor. At the cellular level, the model uses the cellular Potts model based on system-energy reduction to describe endothelial cell migration, growth, division, cellular adhesion, and the evolving structure of the stroma. Numerical simulations show: 1), different tumor-secreted pro-angiogenic factor gradient profiles dramatically affect capillary sprout morphology; 2), average sprout extension speeds depend on the proximity of the proliferating region to the sprout tip, and the coordination of cellular functions; and 3), inhomogeneities in the extravascular tissue lead to sprout branching and anastomosis, phenomena that emerge without any prescribed rules. This model provides a quantitative framework to test hypotheses on the biochemical and biomechanical mechanisms that control tumor-induced angiogenesis.  (+info)

*List of MeSH codes (D16)

... angiogenesis modulating agents MeSH D27.505.696.377.077.077 --- angiogenesis inducing agents MeSH D27.505.696.377.077.099 --- ... fibrin modulating agents MeSH D27.505.519.421.500 --- antifibrinolytic agents MeSH D27.505.519.421.750 --- fibrinolytic agents ... lipotropic agents MeSH D27.505.954.248 --- antineoplastic agents MeSH D27.505.954.248.025 --- angiogenesis inhibitors MeSH ... anti-allergic agents MeSH D27.505.954.122 --- anti-infective agents MeSH D27.505.954.122.085 --- anti-bacterial agents MeSH ...

*Targeted therapy of lung cancer

Targeted agents are designed to be selective in their effects by modulating the activity of proteins necessary and essential ... for oncogenesis and maintenance of cancer, particularly enzymes driving the uncontrolled growth, angiogenesis, invasiveness, ... Many targeted agents appear more active in certain NSCLC variants. Given that c-SCLC contains components of NSCLC, and that the ... Targeted agents are beginning to permit the design of more rational treatment regimens for non-small cell lung cancer (NSCLC), ...

*Tasquinimod

... the tumor microenvironment and counteracts cancer development by inhibiting angiogenesis and metastasis and by modulating the ... by laboratories at Johns Hopkins School of Medicine and Active Biotech Research AB identified tasquinimod as the lead agent for ... Tasquinimod reduces tumor angiogenesis; but its anti-angiogenic effects do not appear to be linked to vascular endothelial ...

*Gold nanoparticles in chemotherapy

... thereby reducing tumor agents and increasing efficiency of electron transfer by modulating the activity of glucose oxidase. ... The process of angiogenesis involves the use of both promoters and inhibitors, balancing the process by only forming new blood ... As AuNPs reduce angiogenesis, rheumatoid arthritis is reduced as a result. Chamberland et al studied the use of anti-TNF ... The issue of angiogenesis describes the formation of new blood vessels, which not only increased spread of cancerous cells, but ...

*Hedgehog signaling pathway

The most common way to target this pathway is modulate SMO. Antagonist and agonist of SMO have already shown to affect the ... Hedgehog signaling also appears to be a crucial regulator of angiogenesis and thus metastasis. Activation of the Hedgehog ... The most clinically advanced SMO targeting agents are cyclopamine-competitive. Itraconazole (Sporanox) has also been shown to ... Velcheti, V (2007). "Hedgehog signaling is a potent regulator of angiogenesis in small cell lung cancer". Medical Hypotheses. ...

*Hsp90

For example, the Hsp90 inhibitor geldanamycin has been used as an anti-tumor agent. The drug was originally thought to function ... Together with its co-chaperones, Hsp90 modulates tumour cell apoptosis "mediated through effects on AKT, tumor necrosis factor ... angiogenesis, and metastasis. Hsp90 plays apparently conflicting roles in the cell, as it is essential for both the creation ... Both are important for de novo angiogenesis that is required for tumour growth beyond the limit of diffusion distance of oxygen ...

*Sphingosine-1-phosphate

In addition, S1P modulates the proliferation of skin cells. This in particular applies to keratinocytes while fibroblasts are ... Administration of S1P has been shown to protect oocytes from chemotherapeutic agents in vitro, as well as in vivo from ... In the vascular system, S1P regulates angiogenesis, vascular stability, and permeability. In the immune system, it is now ... angiogenesis Given its role in creating new blood vessels, scientists recognize S1P as vital to human health - and a player in ...

*Metastatic breast cancer

TNC is an adhesion-modulating extracellular matrix glycoprotein. It is highly expressed in tumor stroma and stimulates tumor- ... Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Cancer Biology, Vol. 12, 2002: pp ... potent bone resorptive agents) and stimulating bone resorption. After the breast-cancer cells have left the primary tumor, they ... MMP-2 is unlike other MMP's as its activity is modulated by metalloproteases called tissue inhibitor of metalloproteases (TIMP ...

*Reactive oxygen species

ROS have been shown to induce transcription factors and modulate signaling molecules involved in angiogenesis (MMP, VEGF) and ... The role of ROS in promoting tumor proliferation is further supported by the observation that agents with potential to inhibit ... In fact, most of the chemotherapeutic and radiotherapeutic agents kill cancer cells by augmenting ROS stress. The ability of ... Due to the dual role of ROS, both prooxidant and antioxidant-based anticancer agents have been developed. However, modulation ...

*Galectin-3

... also helps promote angiogenesis. The roles of galectins and galectin-3, in particular, in cancer have been heavily ... Galectin-3 associates with the primary cilium and modulates renal cyst growth in congenital polycystic kidney disease. A ... targeting the actions of galectin-3 poses a promising therapeutic strategy for the development of effective therapeutic agents ... angiogenesis, metastasis, apoptosis. Galectin-3 is encoded by a single gene, LGALS3, located on chromosome 14, locus q21-q22. ...

*Yihai Cao

Cao, Yihai (2007-09-01). "Angiogenesis modulates adipogenesis and obesity". The Journal of Clinical Investigation. 117 (9): ... "Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome". ... "Angiogenesis in Obesity & Diabetes , School of Medicine". medicine.dundee.ac.uk. Retrieved 2017-02-22. "Axel Hirsch Prize for ... Cao, Y.; Chen, C.; Weatherbee, J. A.; Tsang, M.; Folkman, J. (1995-12-01). "gro-beta, a -C-X-C- chemokine, is an angiogenesis ...

*Prostaglandin EP3 receptor

DG-041, a highly selective EP3 antagonist, has been proposed to warrant further study as anti-thrombosis agent. GR 63799X, MB- ... Takeuchi K, Kato S, Amagase K (2010). "Prostaglandin EP receptors involved in modulating gastrointestinal mucosal integrity". ... and a tumor-associated angiogenesis and lymphangiogenesis. Many drugs that act on EP3 and, often, other prostaglandin receptors ...

*CYP2C9

Where classes of agents are listed, there may be exceptions within the class. Inhibitors of CYP2C9 can be classified by their ... "Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway". J. Lipid Res. 55 ... Zhang G, Kodani S, Hammock BD (Jan 2014). "Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and ... Antimicrobial Agents and Chemotherapy. 47 (11): 3464-9. doi:10.1128/AAC.47.11.3464-3469.2003. PMC 253795 . PMID 14576103. ...

*Leptin

It modulates the immune response to atherosclerosis, of which obesity is a predisposing factor. Exogenous leptin can promote ... There are nutritional supplements and pharmacological agents capable of directing these factors and improving both conditions. ... angiogenesis and bone formation. More recently, leptin has been recognised as a cytokine factor as well as with pleiotropic ... Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI (August 1998). "Leptin modulates the T-cell immune response and ...

*Copper peptide GHK-Cu

On the basis of the available data, it was proposed that GHK-Cu functions by modulating copper intake into cells. In the late ... 2005:549-563 Uno H, Kurata S "Chemical agents and peptides affect hair growth. J Invest Dermatol. 1993; 101(1 Suppl):143S-147S ... angiogenesis, and wound closure in both wound chambers and full thickness wounds. Biotinylated GHK-Cu was incorporated into a ... Thus, GHK-Cu's ability to bind copper and to modulate its tissue level is a key factor determining its biological activity. " ...

*S1PR1

Gα12 and Gα13 modulate cytoskeletal remodeling and cell-shape changes and Gαq modulates several cellular effector functions. ... It was also shown in vivo that S1P synergizes with angiogenic factors such as FGF-2 and VEGF in inducing angiogenesis and ... Fingolimod, a drug which internalizes the receptor, is approved as a disease modifying agent in MS. There are other Sphingosine ... Depending on the G protein coupled with the S1PR1, diverse cellular effects are achieved: Gαi and Gαo modulate cellular ...

*Antihistamine

Norrby K (1995). "Evidence of a dual role of endogenous histamine in angiogenesis". Int J Exp Pathol. 76 (2): 87-92. PMC ... Consequently, unlike the H1-antihistamines which are sedating, H3-antihistamines have stimulant and cognition-modulating ... Examples include: Cimetidine Famotidine Lafutidine Nizatidine Ranitidine Roxatidine Tiotidine These are experimental agents and ... Histamine also promotes angiogenesis. Antihistamines suppress the histamine-induced wheal response (swelling) and flare ...

*Tamoxifen

4-OHT binds to ER, the ER/tamoxifen complex recruits other proteins known as co-repressors and then binds to DNA to modulate ... Clinical trials on angiogenesis inhibitors have been underway since 1992 using myriad different drugs. The Harvard researchers ... Cole MP, Jones CT, Todd ID (Jun 1971). "A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ... It is a nonsteroidal agent with potent antiestrogenic properties which compete with estrogen for binding sites in breast and ...

*Purinergic signalling

These effects are modulated by the P2RY1 and the P2Y12 receptors. The P2RY1 receptor is responsible for shape change in ... Like most immunomodulating agents, ATP can act either as an immunosuppressive or an immunostimulatory factor, depending on the ... Adenosine receptors affect bronchial reactivity, endothelial permeability, fibrosis, angiogenesis and mucus production. ... Extracellular purines modulate fibroblast proliferation by binding onto adenosine receptors and P2 receptors to influence ...

*ANGPTL4

... modulating agents and structure-function relationships". Expert Rev Proteomics. 9 (3): 181-199. doi:10.1586/epr.12.12. PMID ... ANGPTL4-deficient mice exhibit delayed wound reepithelialization with impaired keratinocyte migration, angiogenesis and altered ... ANGPTL4 plays an important role in numerous cancers and is implicated in the metastatic process by modulating vascular ... "ANGPTL4 modulates vascular junction integrity by integrin signaling and disruption of intercellular VE-cadherin and claudin-5 ...

*MECOM

It has been observed that it not only induces apoptosis but can also inhibit the cell cycle, and has marked anti-angiogenesis ... Arsenic is a fairly ancient human therapeutic agent, however it has only recently returned to the forefront of cancer treatment ... "Phosphorylation of the leukemic oncoprotein EVI1 on serine 196 modulates DNA binding, transcriptional repression and ... HSCs secrete angiopoietin, and its receptor molecule Tie2 has been implicated in angiogenesis of tumors in both humans and mice ...

*TGF beta 1

"Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis". Proc. ... "Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation". J. ... "Transforming growth factor-beta inhibits human antigen-specific CD4+ T cell proliferation without modulating the cytokine ...

*Germinal center B-cell like diffuse large B-cell lymphoma

Combining ABT-737 with second agents that inactivate Mcl-1 may reduce this effect. ABT-737 has demonstrated single-agent ... mTOR inhibitors lead to cell cycle arrest in the G1 phase and also inhibits tumor angiogenesis by reducing synthesis of VEGF. A ... The mechanism of action of Rituximab against DLBCL is not fully understood, but studies suggest that rituximab modulates ... Reduced susceptibility to apoptosis increases the resistance of cancer cells to radiation and cytotoxic agents. B-cell lymphoma ...

*Withaferin A

"A Novel MMP-2 Inhibitor 3-azidowithaferin A (3-azidoWA) Abrogates Cancer Cell Invasion and Angiogenesis by Modulating ... Therefore, withaferin A can be a potential therapeutic agent for the treatment of cervical cancer without major side effects. ... 2004). "Withaferin A is a potent inhibitor of angiogenesis". Angiogenesis. 7 (2): 115-122. doi:10.1007/s10456-004-1026-3. PMID ... It is a potent inhibitor of angiogenesis. Anti-angiogenic and anti-tumor activity of withaferin A is due to the inhibition of ...

*Tumor hypoxia

Niacinamide, the active form of vitamin B3, acts as a chemo- and radio-sensitizing agent by enhancing tumor blood flow, thereby ... Release of lactate from tumor cells through MCT-4 was sufficient to stimulate angiogenesis and tumor growth through an IL-8- ... Hyaluronan is a glycosaminoglycan polymer critical for maintaining extracellular matrix integrity and modulating cell-cell ... Hypoxia: targeting the tumor; R.G. Boyle and S. Travess; Anticancer Agents Med. Chem. 64:281, 2006. Targeting tumors with ...

*Ubiquitin

These effects can all modulate the transcription of genes. Deubiquitinating enzymes (DUBs) oppose the role of ubiquination by ... Dou QP, Li B (August 1999). "Proteasome inhibitors as potential novel anticancer agents". Drug Resistance Updates. 2 (4): 215- ... HIF activates downstream targets such as the vascular endothelial growth factor (VEGF), promoting angiogenesis. Mutations in ... Vries EG, Verweij J (2000). "Clinical Cancer Research 2000: New Agents and Therapies". Drug Resistance Updates. 3 (4): 197-201 ...
article{63d89b76-6152-4488-8b69-f0d4dcc17364, abstract = {ObjectiveTo evaluate two algorithms for prediction of preeclampsia in a population of nulliparous women in Norway. DesignProspective screening study. SettingNational Centre for Fetal Medicine in Trondheim, Norway. PopulationFive hundred and forty-one nulliparous women. MethodsThe women were examined between 11(+0) and 13(+6)weeks with interviews for maternal characteristics and measurements of mean arterial pressure, uterine artery pulsatility index, pregnancy-associated plasma protein A and placental growth factor. The First Trimester Screening Program version 2.8 by The Fetal Medicine Foundation (FMF) was compared with the Preeclampsia Predictor TM version 1 revision 2 by Perkin Elmer (PREDICTOR). Main outcome measuresPrediction of preeclampsia requiring delivery before 37weeks, before 42weeks and late preeclampsia (delivery after 34weeks). ResultsThe performance of the two algorithms was similar, but quite poor, for prediction of ...
The views presented here are those of the author and are not to be construed as official or reflecting the views of the Uniformed Services University of the Health Sciences, the Department of Defense or the U.S. Government ...
PicFlips is a way to bring your parties to life with the newest craze in customized party favors. In less than 90 seconds, the video clip is transformed into a
... : atrophy in a variety of ways sometimes by a gradual diminution of the. serpine1 mutation iii lt ue the len cth of time that patients remain free
Product information will be uploaded soon. If you have any questions, comments, or concerns please contact [email protected]
Buy our Recombinant Human SERPINA10 protein. Ab162436 is a full length protein produced in Wheat germ and has been validated in WB, ELISA. Abcam provides free…
recently i have been getting some weird skin rash and really dry skin. the dry skin is usually on the back of my arms where my triceps are. also in between my fingers i get this tiny little white dots ...
Ask your health care provider any questions you may have about how to use Serpina.. STORAGE. Store Serpina at 77 degrees F (25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Serpina out of the reach of children and away from pets.. MORE INFO:. Ingredients: Sarpagandha (Rauwolfia serpentina).. SAFETY INFORMATION. Do NOT use Serpina if:. ...
Ask your health care provider any questions you may have about how to use Serpina.. STORAGE. Store Serpina at 77 degrees F (25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Serpina out of the reach of children and away from pets.. MORE INFO:. Ingredients: Sarpagandha (Rauwolfia serpentina). ...
Ask your health care provider any questions you may have about how to use Serpina.. STORAGE. Store Serpina at 77 degrees F (25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Serpina out of the reach of children and away from pets.. MORE INFO:. Ingredients: Sarpagandha (Rauwolfia serpentina).. SAFETY INFORMATION. Do NOT use Serpina if:. ...
Serpina3n: latus, stain with aniline oil gential violet, steaming. serpina3n mouse (lus diseases, other than typhoid fever, in which he
YES if it is a skin cancer (basal or squamous cell carcinoma) or a uterine cervical cancer in situ, as long as it has been successfully treated.. For any other type of cancer: consult with Héma-Québec staff.. ...
Buy SERPINA1 antigen, ALPHA 1 ANTITRYPSIN Antigen-NP_000286.3 (MBS238024) product datasheet at MyBioSource, Antigens. Application: ELISA (EIA)

Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer - Full Text View -...Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer - Full Text View -...

Immunosuppressive Agents. Immunologic Factors. Physiological Effects of Drugs. Angiogenesis Inhibitors. Angiogenesis Modulating ... Antineoplastic Agents. Antiviral Agents. Anti-Infective Agents. Enzyme Inhibitors. ... More than 2 weeks since prior and no concurrent thrombolytic agents. * Anticoagulation therapy with warfarin or low molecular ...
more infohttps://clinicaltrials.gov/ct2/show/study/NCT00112528?show_locs=Y

First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX - Full Text View - ClinicalTrials.govFirst Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX - Full Text View - ClinicalTrials.gov

Angiogenesis Inhibitors. Angiogenesis Modulating Agents. Growth Substances. Physiological Effects of Drugs. Growth Inhibitors. ... Antineoplastic Agents. Antimetabolites. Molecular Mechanisms of Pharmacological Action. Antimetabolites, Antineoplastic. ...
more infohttps://www.clinicaltrials.gov/ct2/show/NCT00384176

Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer - Full Text View -...Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer - Full Text View -...

Antineoplastic Agents. Angiogenesis Inhibitors. Angiogenesis Modulating Agents. Growth Substances. Physiological Effects of ... Ling et al, 2007) A Chinese phase III clinical trial in advanced non-small-cell lung cancer, endostar--a new angiogenesis ... Ling et al, 2007) A Chinese phase III clinical trial in advanced non-small-cell lung cancer, endostar--a new angiogenesis ... It is hypothesized that other anti-angiogenic agents such as endostar, may augment the effect of chemotherapy regimens in CRC. ...
more infohttps://www.clinicaltrials.gov/ct2/show/NCT00853684?term=colon+cancer+AND+Capecitabine&rank=36

Treatment for CI-DME in Eyes With Very Good VA Study - Full Text View - ClinicalTrials.govTreatment for CI-DME in Eyes With Very Good VA Study - Full Text View - ClinicalTrials.gov

Antineoplastic Agents, Immunological. Antineoplastic Agents. Angiogenesis Inhibitors. Angiogenesis Modulating Agents. Growth ... Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes ...
more infohttps://www.clinicaltrials.gov/ct2/show/NCT01909791?term=protocol+v&rank=1

Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients - Full Text View - ClinicalTrials.govMaintenance Therapy in Acute Myeloid Leukemia (AML) Patients - Full Text View - ClinicalTrials.gov

Angiogenesis Inhibitors. Angiogenesis Modulating Agents. Growth Substances. Growth Inhibitors. Antineoplastic Agents. To Top ...
more infohttps://clinicaltrials.gov/ct2/show/NCT00957385

Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma - Full Text View - ClinicalTrials.govLenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma - Full Text View - ClinicalTrials.gov

Angiogenesis Inhibitors. Angiogenesis Modulating Agents. Growth Substances. Growth Inhibitors. Antineoplastic Agents. ... I. Determine the maximum tolerated dose (MTD) of single agent lenalidomide in subjects with AIDS-related KS. (Phase I) II. ... Patients on erythropoietin-stimulating agents (ESA) unless also on therapeutic anticoagulation. *Patients with CD4 , 50 mm^3 ...
more infohttps://clinicaltrials.gov/ct2/show/NCT01057121?recr=Open&cond=%22Sarcoma%2C+Kaposi%22&rank=8

A Category Names List - Drug Information Portal - U.S. National Library of MedicineA Category Names List - Drug Information Portal - U.S. National Library of Medicine

Angiogenesis Modulating Agents (29). Angiotensin II Type 1 Receptor Blockers (21) • Agents that antagonize ANGIOTENSIN II TYPE ... Anti-Angiogenesis Effect (0) see Angiogenesis Inhibitors. Anti-Anxiety Agents (86) • Agents that alleviate ANXIETY, tension, ... Angiogenesis Inducing Agents (2). Angiogenesis Inhibitors (29) • Agents and endogenous substances that antagonize or inhibit ... Anti-Mycobacterial Agents (0) see Anti-Bacterial Agents. Anti-Obesity Agents (24) • Agents that increase energy expenditure and ...
more infohttps://druginfo.nlm.nih.gov/drugportal/drug/categories

A Category Names List - Drug Information Portal - U.S. National Library of MedicineA Category Names List - Drug Information Portal - U.S. National Library of Medicine

Angiogenesis Modulating Agents (29). Angiotensin II Type 1 Receptor Blockers (21) • Agents that antagonize ANGIOTENSIN II TYPE ... Anti-Angiogenesis Effect (0) see Angiogenesis Inhibitors. Anti-Anxiety Agents (87) • Agents that alleviate ANXIETY, tension, ... Angiogenesis Inducing Agents (2). Angiogenesis Inhibitors (29) • Agents and endogenous substances that antagonize or inhibit ... Anti-Mycobacterial Agents (0) see Anti-Bacterial Agents. Anti-Obesity Agents (24) • Agents that increase energy expenditure and ...
more infohttps://druginfo.nlm.nih.gov/drugportal/jsp/drugportal/drugNamesAndCategories.jsp

Spindle Cell Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical TrialsSpindle Cell Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

Angiogenesis Inhibitors. Phase 2. 8. Angiogenesis Modulating Agents. Phase 2. 9. Antibodies. Phase 2. ...
more infohttp://www.malacards.org/card/spindle_cell_carcinoma

Malignant Epithelial Mesothelioma disease: Malacards - Research Articles, Drugs, Genes, Clinical TrialsMalignant Epithelial Mesothelioma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

Angiogenesis Inhibitors. Phase 2. 46. Dihematoporphyrin Ether. Phase 2. 47. Angiogenesis Modulating Agents. Phase 2. ... Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB- ...
more infohttps://www.malacards.org/card/malignant_epithelial_mesothelioma

A novel microtubule-modulating agent EM011 inhibits angiogenesis by repressing the HIF-1α axis and disrupting cell polarity and...A novel microtubule-modulating agent EM011 inhibits angiogenesis by repressing the HIF-1α axis and disrupting cell polarity and...

Here we show that EM011 (9-bromonoscapine), a microtubule-modulating agent, inhibits a spectrum of angiogenic events by ... Here we show that EM011 (9-bromonoscapine), a microtubule-modulating agent, inhibits a spectrum... ... the master regulator of tumor angiogenesis. Thus, microtubule-disrupting agents that perturb the HIF-1α axis and ... the master regulator of tumor angiogenesis. Thus, microtubule-disrupting agents that perturb the HIF-1α axis and ...
more infohttp://oxfordindex.oup.com/view/10.1093/carcin/bgs200

Abstract - International Journal of Morphology	Abstract - International Journal of Morphology

KEY WORDS: Endothelium; Exercise; Physiologic Neovascularization; Angiogenesis Modulating Agents.. How to cite this article. ... In this review, the main mechanisms involved in the physiological regulation of vasculogenesis and angiogenesis are addressed. ... angiogenesis). The angiogenic factor that induces morphological and functional changes in the endothelial cells is the VEGFA, ...
more infohttp://www.intjmorphol.com/abstract/?art_id=2512

Angiogenesis modulations in health and disease : practical applications of pro- and antiangiogenesis targets [WorldCat Entities]Angiogenesis modulations in health and disease : practical applications of pro- and antiangiogenesis targets [WorldCat Entities]

"Angiogenesis Modulating Agents.". http://experiment.worldcat.org/entity/work/data/1433997986#Topic/angiogenesis_modulating_ ... Angiogenesis Modulating Agents.. This is a placeholder reference for a Topic entity, related to a WorldCat Entity. Over time, ... Angiogenesis Inducing Agents.. This is a placeholder reference for a Topic entity, related to a WorldCat Entity. Over time, ... http://experiment.worldcat.org/entity/work/data/1433997986#Topic/angiogenesis_modulating_agents ...
more infohttp://experiment.worldcat.org/entity/work/data/1433997986

The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC PatientsThe Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients

Angiogenesis Modulating Agents. Agents that modulate the PHYSIOLOGIC ANGIOGENESIS process. This is accomplished by endogenous ... Angiogenesis Inducing Agents. Agents that induce or stimulate the PHYSIOLOGIC ANGIOGENESIS process. This is caused by a number ... Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases.. Angiogenesis is a critical step ... Angiogenesis: focusing on the effects of exercise in aging and cancer.. Although it is known that exercise induces angiogenesis ...
more infohttps://www.bioportfolio.com/resources/trial/163943/The-Efficacy-and-Safety-of-Endostar-Combined-With-Taxane-based-Regimens-for.html

Cultrex® In Vitro Angiogenesis Assay Tube Formation Kit - TrevigenCultrex® In Vitro Angiogenesis Assay Tube Formation Kit - Trevigen

... endothelial cells are seeded on a thick gel of Basement Membrane Extract in the presence of angiogenesis modulating agents. If ... Cultrex® In Vitro Angiogenesis Assay Tube Formation Kit. $264.00. The Cultrex® In Vitro Angiogenesis Assay Tube Formation Kit ... Cultrex® In Vitro Angiogenesis Assay Kit provides a cost-effective method for investigation of prospective angiogenesis ... Cultrex® In Vitro Angiogenesis Assay Endothelial Cell Invasion Kit. View Details. $374.00 Add to cart ...
more infohttps://trevigen.com/products-services/physiologic-cell-culture/cell-based-assays/angiogenesis-assays/cultrex-in-vitro-angiogenesis-assay-tube-formation-kit/

Clinical Trial | Sunitinib and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to...Clinical Trial | Sunitinib and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to...

Antiparasitic Agents. Anti-Infective Agents. Antineoplastic Agents. Angiogenesis Inhibitors. Angiogenesis Modulating Agents. ... Must have undergone treatment with ≥ 1 regimen of standard therapy (i.e., cytotoxic chemotherapy, an oral targeted agent, or ... At least 4 weeks since prior treatment with cytotoxic or biologic agents (6 weeks for mitomycin C or nitrosoureas) ... No other concurrent investigational or commercial agents or therapies with the intent to treat the patients malignancy ...
more infohttp://comparetrials.com/compare-clinical-trials/sunitinib-and-hydroxychloroquine-in-treating-patients-with-advanced-solid-tumors-that-have-not-responded-to-chemotherapy

JoVE | Peer Reviewed Scientific Video Journal - Methods and ProtocolsJoVE | Peer Reviewed Scientific Video Journal - Methods and Protocols

Angiogenesis Modulating Agents, Growth and Development, Lymphangiogenesis, Angiogenesis, Mouse Neonatal Retina, ... Angiogenesis plays a key role not only in normal development of organs and tissues, but also in many diseases in which blood ... Angiogenesis is the complex process of new blood vessel formation defined by the sprouting of new blood vessels from a pre- ... In adult life, blood vessels are generally quiescent so angiogenesis is an important target for novel drug development to try ...
more infohttps://www.jove.com/visualize/abstract/25188381/characterization-of-a-spontaneous-retinal-neovascular-mouse-model

JoVE | Peer Reviewed Scientific Video Journal - Methods and ProtocolsJoVE | Peer Reviewed Scientific Video Journal - Methods and Protocols

Angiogenesis Modulating Agents, Wounds and Injuries, Wound healing, mouse, angiogenesis, diabetes mellitus, splint, surgical ... It has been utilized to investigate tumor angiogenesis, drug delivery and stem cell survival and engraftment1,2,6,7. With its ... There is, therefore, an increasing impetus to develop novel agents that promote wound repair. The testing of these has been ... Herein, we demonstrate the efficacy of these procedures by increasing oxidative stress in tissues by oxidant agents and ...
more infohttps://www.jove.com/visualize/abstract/23431364/acute-stress-reduces-wound-induced-activation-microbicidal-potential

SLE-DC-MEDIATED ENHANCED IgG- AND IgA-SECRETING B CELL RESPONSES - Patent applicationSLE-DC-MEDIATED ENHANCED IgG- AND IgA-SECRETING B CELL RESPONSES - Patent application

The invention further provides methods for identifying syndecan- and angiogenesis-modulating agents. [0008] U.S. Pat. No. ... agents. [0042] The term "anti-neoplastic agent" refers to agents that have the functional property of inhibiting the ... 7,713,925 issued to Ekker, et al., entitled, "Syndecans and Angiogenesis" discloses methods and materials related to modulating ... The invention also provides polynucleotides and polynucleotide analogues for modulating angiogenesis, as well as cells and ...
more infohttp://www.patentsencyclopedia.com/app/20120308578

Clinical Trial | Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma MultiformeClinical Trial | Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme

Leprostatic Agents. Anti-Bacterial Agents. Anti-Infective Agents. Angiogenesis Inhibitors. Angiogenesis Modulating Agents ... Antineoplastic Agents, Phytogenic. Antineoplastic Agents Therapeutic Uses. Pharmacologic Actions. Radiation-Sensitizing Agents ... Concurrent use of other anti-cancer agents or treatments.. *No exclusion to this study will be based on race. Minorities will ... Patients must have recovered from the toxic effects of prior therapy: 4 weeks from any investigational agents, two weeks from ...
more infohttp://comparetrials.com/compare-clinical-trials/irinotecan-plus-lenalidomide-in-adult-patients-with-recurrent-glioblastoma-multiforme-2

Patente US7169179 - Drug delivery device and method for bi-directional drug delivery - Google PatentesPatente US7169179 - Drug delivery device and method for bi-directional drug delivery - Google Patentes

... and/or antirestenotic agents are delivered to the wall of a blood vessel and antithrombotic agents, antiplatelet agents, and/or ... different quantities of therapeutic agents, or different release profiles of the same or different therapeutic agents in ... In particular, the invention relates to the delivery of different therapeutic agents, ... or antiangiogenic agents and/or vasodilators to a blood vessel. In one embodiment, antiproliferative, antineoplastic, ...
more infohttp://www.google.es/patents/US7169179

List of MeSH codes (D16) - WikipediaList of MeSH codes (D16) - Wikipedia

... angiogenesis modulating agents MeSH D27.505.696.377.077.077 --- angiogenesis inducing agents MeSH D27.505.696.377.077.099 --- ... fibrin modulating agents MeSH D27.505.519.421.500 --- antifibrinolytic agents MeSH D27.505.519.421.750 --- fibrinolytic agents ... lipotropic agents MeSH D27.505.954.248 --- antineoplastic agents MeSH D27.505.954.248.025 --- angiogenesis inhibitors MeSH ... anti-allergic agents MeSH D27.505.954.122 --- anti-infective agents MeSH D27.505.954.122.085 --- anti-bacterial agents MeSH ...
more infohttps://en.wikipedia.org/wiki/List_of_MeSH_codes_(D16)

Plus itPlus it

... therapeutic efforts focused on modulating angiogenesis are increasing (32, 33, 34) . The initial agent investigated in this ... Is VEGF the best target if we wish to modulate angiogenesis in patients with MM? Although both preclinical and clinical data ... Patients receiving drugs and agents that inhibit or induce this enzyme, including some antifungal agents (45) and macrolide ... angiogenesis-modulating properties (34 , 61) . Thalidomide is a potent suppressor of VEGF in a number of in vitro models (62) ...
more infohttps://clincancerres.aacrjournals.org/content/10/1/88

Oglufanide - DrugBankOglufanide - DrugBank

Angiogenesis Modulating Agents. *Antidotes. *Antineoplastic Agents. *Cardiovascular Agents. *Growth Inhibitors. *Growth ...
more infohttps://www.drugbank.ca/drugs/DB05779

Omacetaxine mepesuccinate - DrugBankOmacetaxine mepesuccinate - DrugBank

... is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological ... Angiogenesis Modulating Agents. *Antineoplastic Agents. *Antineoplastic Agents, Phytogenic. *Antineoplastic and ... is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological ...
more infohttps://www.drugbank.ca/drugs/DB04865
  • 9. continued) Patients who receive irinotecan for non-therapeutic purposes unrelated to this study (such as presurgically for obtaining pharmacology data for the agent) will be eligible to enter the study provided they have recovered from the toxic effects of the agent if any. (comparetrials.com)
  • A drug delivery device is provided with openings for directional delivery of a plurality of therapeutic agents to blood vessels or other lumens or organs. (google.es)
  • In particular, the invention relates to the delivery of different therapeutic agents, different quantities of therapeutic agents, or different release. (google.es)
  • a bioerodible barrier layer disposed in the openings at a radially intermediate position with respect to said exterior surface and said interior surface of the medical device, and wherein said first therapeutic agent is provided at a radially exterior position with respect to the barrier layer and said second therapeutic agent is provided at a radially interior position with respect to the barrier layer. (google.es)
  • 5. The device of claim 4 , wherein the second therapeutic agent is selected from the group consisting of an antirestenotic agent, an antithrombotic agent, an antiplatelet agent, an anti-inflammatory agent, and a vasodilator. (google.es)
  • 7. The device of claim 1 , wherein the barrier layer has a predetermined erosion time which is longer than erosion times of biodegradable matrices containing the first and second therapeutic agents. (google.es)
  • 8. The device of claim 1 , wherein the first therapeutic agent is contained within a biodegradable matrix and the first therapeutic agent has a concentration variation within the matrix. (google.es)
  • Apart from the crucial functions of the vessels, excessive vascular growth with angiogenesis can lead to undesirable conditions such as allograft rejection after organ transplantation and growth of tumors beyond the limits of oxygen diffusion from the existing vasculature. (arvojournals.org)
  • Ling et al, 2007) A Chinese phase III clinical trial in advanced non-small-cell lung cancer , endostar--a new angiogenesis inhibitor prolonged the overall survival, time to progression and improved response rate. (clinicaltrials.gov)
  • FOLFOX4 plus Avastin has been suggested as firstline regimen for advanced colorectal cancer by NCCN, a new angiogenesis inhibitor, known as Endostar(Recombinant Human Endostatin), prolonge. (bioportfolio.com)
  • To study the impact of endostar combined with docetaxel and cisplatin on the angiogenesis of non-small cell lung cancer, patients will be randomly assigned to the group one (endostar combi. (bioportfolio.com)
  • By splinting the wound, the repair process is then dependent on epithelialization, cellular proliferation and angiogenesis, which closely mirror the biological processes of human wound healing. (jove.com)
  • Targeted agents are designed to be selective in their effects by modulating the activity of proteins necessary and essential for oncogenesis and maintenance of cancer, particularly enzymes driving the uncontrolled growth, angiogenesis, invasiveness, and metastasis characteristic of malignant tumors. (wikipedia.org)
  • This is the first report to describe a previously unrecognized, antiangiogenic property of a noscapinoid, EM011, and provides evidence for novel anticancer strategies recruited by microtubule-modulating drugs. (oup.com)
  • Xanthohumol is a prenylated chalcone naturally found in hop plants, previously reported to be an effective anticancer agent in various cancer cell lines. (hindawi.com)
  • The transcriptional regulation of ANGPTL4 can be modulated by several transcription factors, including PPAR α , PPAR β / δ , PPAR γ , and HIF-1 α , and nutritional and hormonal conditions. (hindawi.com)
  • Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. (drugbank.ca)
  • According to the available data, 99.7% of all cervical carcinomas occur due to infection by human papillomavirus (HPV), especially HPV-16 and HPV-18, which World Health Organization identified as high risk carcinogenic agents. (hindawi.com)
  • Based on the obtainable data 99.7% of most cervical carcinomas occur because of infection by human papillomavirus AS-604850 AS-604850 (HPV) especially HPV-16 and HPV-18 which World Health Organization defined as risky carcinogenic agents. (exposed-skin-care.net)
  • Our previous study showed that ethanol exposure inhibited embryonic angiogenesis mainly due to the excessive stimulation of reactive oxygen species (ROS) production. (bioportfolio.com)
  • Targeted agents are beginning to permit the design of more rational treatment regimens for non-small cell lung cancer (NSCLC), which comprises about 80% to 85% of all lung cancers. (wikipedia.org)
  • Many targeted agents appear more active in certain NSCLC variants. (wikipedia.org)
  • Given that c-SCLC contains components of NSCLC, and that the chemoradioresistance of NSCLC components impact the effectiveness of c-SCLC treatment, these agents may permit the design of more rational treatment regimens for c-SCLC. (wikipedia.org)
  • Angiogenesis is a critical step in the progression of almost all human malignancies and some other life-threatening diseases. (bioportfolio.com)
  • Amongst these are the chemotherapeutic agents currently used as advanced and metastatic cervical cancer treatment options, such as cisplatin, paclitaxel, topotecan, cetuximab, and bevacizumab. (hindawi.com)
  • and predicting the efficacy of a therapy with a pharmaceutical agent for treating the patient, wherein a decrease in the overall expression of syndecan-1 in the patient cells when compared to the expression of syndecan-1 in normal cells indicates a predisposition to responsiveness to anti-neoplastic agent therapy, wherein the therapy comprises administering an effective amount of the pharmaceutical agent to the patient. (patentsencyclopedia.com)
  • While there have been no randomized clinical trials of targeted agents in combined small-cell lung carcinoma (c-SCLC),[citation needed] some small case series suggest that some may be useful in c-SCLC. (wikipedia.org)
  • Patients must have recovered from the toxic effects of prior therapy: 4 weeks from any investigational agents, two weeks from vincristine, 6 weeks from nitrosoureas, 3 weeks from procarbazine administration, and 1 week for non-cytotoxic agents, e.g., interferon, tamoxifen, cis-retinoic acid, etc. (radiosensitizer does not count). (comparetrials.com)
  • The Cultrex® In Vitro Angiogenesis Assay Tube Formation Kit is designed to interrogate endothelial assembly in response to compounds and soluble factors. (trevigen.com)
  • The purpose of this study is to characterize the induction of pathologic angiogenesis in this mouse model. (jove.com)
  • Agents that modulate the PHYSIOLOGIC ANGIOGENESIS process. (bioportfolio.com)
  • Sulforaphane [1- isothiocyanato-(4R)- methylsulfinyl)-butane], found in broccoli and other cruciferous vegetables, is a naturally occurring cancer chemopreventive agent, and is provided as a control inhibitor to visualize this process. (trevigen.com)
  • Nevertheless at present the usage of these real estate agents leads to medical complications and various marks of toxicities such as for example nausea vomiting discomfort exhaustion and anemia . (exposed-skin-care.net)
  • We hypothesized that (a) acute psychological stress reduces wound-induced activation of microbicidal potential of human monocyte-derived macrophages (HMDM), and (b) that these reductions are modulated by stress hormone release. (jove.com)